PMID- 23722226
OWN - NLM
STAT- MEDLINE
DCOM- 20140124
LR  - 20190221
IS  - 1479-6821 (Electronic)
IS  - 1351-0088 (Linking)
VI  - 20
IP  - 4
DP  - 2013 Aug
TI  - Assessing RET/PTC in thyroid nodule fine-needle aspirates: the FISH point of 
      view.
PG  - 527-36
LID - 10.1530/ERC-13-0157 [doi]
AB  - RET/PTC rearrangement and BRAF(V600E) mutation are the two prevalent molecular 
      alterations associated with papillary thyroid carcinoma (PTC), and their 
      identification is increasingly being used as an adjunct to cytology in diagnosing 
      PTC. However, there are caveats associated with the use of the molecular approach 
      in fine-needle aspiration (FNA), particularly for RET/PTC, that should be taken 
      into consideration. It has been claimed that a clonal or sporadic presence of 
      this abnormality in follicular cells can distinguish between malignant and benign 
      nodules. Nevertheless, the most commonly used PCR-based techniques lack the 
      capacity to quantify the number of abnormal cells. Because fluorescence in situ 
      hybridization (FISH) is the most sensitive method for detecting gene 
      rearrangement in a single cell, we compared results from FISH and conventional 
      RT-PCR obtained in FNA of a large cohort of consecutive patients with suspicious 
      nodules and investigated the feasibility of setting a FISH-FNA threshold capable 
      of distinguishing non-clonal from clonal molecular events. For this purpose, a 
      home brew break-apart probe, able to recognize the physical breakage of RET, was 
      designed. While a >/=3% FISH signal for broken RET was sufficient to distinguish 
      nodules with abnormal follicular cells, only samples with a >/=6.8% break-apart 
      FISH signal also exhibited positive RT-PCR results. On histological analysis, all 
      nodules meeting the >/=6.8% threshold proved to be malignant. These data 
      corroborate the power of FISH when compared with RT-PCR in quantifying the 
      presence of RET/PTC in FNA and validate the RT-PCR efficiency in detecting clonal 
      RET/PTC alterations.
FAU - Caria, Paola
AU  - Caria P
AD  - Department of Biomedical Sciences, M. Aresu Surgical Sciences, University of 
      Cagliari, Cittadella Universitaria, Monserrato (Cagliari), Italy.
FAU - Dettori, Tinuccia
AU  - Dettori T
FAU - Frau, Daniela V
AU  - Frau DV
FAU - Borghero, Angela
AU  - Borghero A
FAU - Cappai, Antonello
AU  - Cappai A
FAU - Riola, Alessia
AU  - Riola A
FAU - Lai, Maria L
AU  - Lai ML
FAU - Boi, Francesco
AU  - Boi F
FAU - Calo, Piergiorgio
AU  - Calo P
FAU - Nicolosi, Angelo
AU  - Nicolosi A
FAU - Mariotti, Stefano
AU  - Mariotti S
FAU - Vanni, Roberta
AU  - Vanni R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130627
PL  - England
TA  - Endocr Relat Cancer
JT  - Endocrine-related cancer
JID - 9436481
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - IM
MH  - Biopsy, Fine-Needle
MH  - Carcinoma/*genetics
MH  - Carcinoma, Papillary
MH  - Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Proto-Oncogene Proteins B-raf/genetics
MH  - Proto-Oncogene Proteins c-ret/*genetics
MH  - Thyroid Cancer, Papillary
MH  - Thyroid Neoplasms/*genetics
MH  - Thyroid Nodule/*genetics
OTO - NOTNLM
OT  - FISH
OT  - RET/PTC
OT  - molecular genetics
OT  - papillary thyroid cancer
OT  - pathogenesis
EDAT- 2013/06/01 06:00
MHDA- 2014/01/25 06:00
CRDT- 2013/06/01 06:00
PHST- 2013/06/01 06:00 [entrez]
PHST- 2013/06/01 06:00 [pubmed]
PHST- 2014/01/25 06:00 [medline]
AID - ERC-13-0157 [pii]
AID - 10.1530/ERC-13-0157 [doi]
PST - epublish
SO  - Endocr Relat Cancer. 2013 Jun 27;20(4):527-36. doi: 10.1530/ERC-13-0157. Print 
      2013 Aug.